Applied Biosystems Launches Genotyping Service Provider Program.

SNPlex Program Delivers Comprehensive Solution, Broadens Access to Technology for the Study of Genetic Variations

FOSTER CITY, Calif. -- Applied Biosystems (NYSE:ABI), an Applera Corporation business, today announced that it has established a global genotyping service provider program for scientists interested in the study of how specific genetic variations may impact health or disease. The SNPlex[TM] Service Provider Program was created for research laboratories that do not have access to capillary electrophoresis (CE) genetic analysis instrument systems. The goal of the program is to provide these researchers with a comprehensive solution for genotyping research through the global service providers participating in the program.

The providers in the program include the Chinese National Human Genome Center (China); DNAVision (Belgium); IntegraGen, Inc. (France); Medical Solutions Geneservice (United Kingdom); the University of California at Los Angeles DNA Sequencing and Genotyping Core Facility (United States); and Vanderbilt University DNA Sequencing and Genotyping Facility (United States).

High-throughput genotyping services offered through the program will enable researchers to study large populations of individuals to gain an understanding of genetic areas of interest and further expand research into potentially finding cures for a variety of diseases that include cancer, heart disease and diabetes, among others. The program members will provide assistance with medium to large-scale genotyping research, such as validation or fine mapping studies that require obtaining high-throughput single nucleotide polymorphism (SNP) data. SNPs are variations in DNA sequence that are believed to affect how diseases develop and determine how a drug may affect a particular disorder.

Applied Biosystems is a global leader in the development and commercialization of instrument-based systems, consumables, software, and services for the life-science market. The SNPlex Service Provider Program is based on the SNPlex[TM] Genotyping System, which consists of custom designed assays, universal core reagents, analysis software, and fully supported system documentation that are optimized for the use on Applied Biosystems' CE platforms. The program provides a broad range of support, including planning, sample extraction, genotyping, data interpretation and statistical analysis through the participating service providers.

The Chinese National Human Genome Center has used the SNPlex genotyping system in conjunction with Applied Biosystems' CE sequencing platforms to lead many national and international genomics research projects related to large scale DNA sequencing, functional genomics, proteomics, and SNP detection.

"The Chinese National Human Genome Center has undertaken many projects in screening candidate genes for disease associations in pedigrees or populations and in our experience the SNPlex System is ideal for this kind of research," said Dr. WeiZhi Chen, M.D. and chief technology officer at the Chinese National Human Genome Center. "Our involvement in this program demonstrates our commitment to delivering highly customized genotyping services to the research community."

Scientists at UCLA's GenoSeq Core anticipate that its customers will utilize SNPlex technology for a wide variety of research, including cancer and neuropsychiatric studies. GenoSeq Core utilized Applied Biosystems SNPlex genotyping and sequencing platforms to establish high-throughput assays and methodologies for more than 240 laboratories in the past year.

"It's not always practical for a researcher to set up a high-throughput assay in their laboratory if the methods are not the main focus of their work," said Dr. Jeanette Papp, director of GenoSeq Core. "GenoSeq Core has the requirements for these experiments in place, including the instrumentation, necessary robotics, bioinformatics, and most importantly, the expertise. This program is another way for us to provide high quality SNP genotyping services to our customers, broaden access to genotyping platforms, and enable them to accelerate their research and business."

Applied Biosystems is supporting the SNPlex Service Provider Program by providing technical and marketing support, which is expected to enhance the participating service providers' ability to deliver advanced genotyping services to customers. Members of the program were chosen based on proficiency in executing the SNPlex chemistry workflow and generating reliable data using GeneMapper[TM] Software for Data Analysis.

"Applied Biosystems believes in partnering with leading laboratories to create programs that broaden access to technologies and software that will enable the acceleration of important research related to the study of disease and other genetic traits," said Phoebe White, senior director of genotyping, Applied Biosystems, "The SNPlex Service Provider Program facilitates access to a complete genotyping analysis system for those who have not scaled up their research and made an investment to purchase on their own."

Further information about the SNPlex Service Provider Program is available at http://info.appliedbiosystems.com/snplex

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should, "planned," and "expect," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) unexpected changes of service providers that participate in the global service provider program could delay test results or lead to varying results; (2) decreasing customer spending for this type of genetic research could affect growth of the service provider program ; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

(c)Copyright 2007. Applied Biosystems. All rights reserved. AB (Design), ABI PRISM, Applied Biosystems, Applera and Celera are registered trademarks and SNPlex is a trademark of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.